<DOC>
	<DOCNO>NCT00055991</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . It yet know whether bexarotene effective preventing breast cancer . PURPOSE : Randomized clinical trial study effectiveness bexarotene prevent breast cancer woman genetic risk develop breast cancer .</brief_summary>
	<brief_title>Bexarotene Preventing Breast Cancer Women Genetic Risk</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether bexarotene modify immunophenotypic marker relate breast cancer progression woman high genetic risk breast cancer . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord menopausal status ( woman uterus menstrual period 1 year v woman 55 year old vs woman 55 year without uterus whose follicle-stimulating hormone postmenopausal range ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral bexarotene daily day 1-28 . - Arm II : Patients receive oral placebo arm I . In arm , treatment continue absence unacceptable toxicity elevation triglyceride great 800 mg/dL . Patients undergo 2 breast biopsy location day 1 29 . Patients follow 30 day . PROJECTED ACCRUAL : A total 100 patient ( 50 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Known carrier BRCA1 BRCA2 mutation Copy laboratory report state result must available review OR At risk carry BRCA1 BRCA2 mutation At least 10 % risk Parmigiana probability model Must least 1 breast never involve cancer irradiate Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status Not specify Life expectancy Not specify Hematopoietic WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hematocrit great 30 % Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) ALT great 1.5 time ULN Alkaline phosphatase great 1.5 time ULN Albumin great 1.5 time ULN No biliary tract disease Renal Creatinine great 1.5 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month , , 1 month study therapy Triglycerides normal Thyroidstimulating hormone thyroxine normal Willing undergo 2 duplicate needle biopsy breast Willing undergo genetic test BRCA1 BRCA2 No uncontrolled hyperlipidemia No nontoxic goiter thyroid enlargement No severe underlie chronic illness disease No uncontrolled diabetes No history pancreatitis No cancer within past year except skin cancer carcinoma situ cervix ( defined date first diagnosis ) No concurrent alcohol use ( great 3 drink equivalent per day ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 1 year since prior chemotherapy neoplasm Endocrine therapy More 3 month since prior postmenopausal hormonal therapy ( include estrogen progestin ) More 3 month since prior tamoxifen selective estrogenreceptor modulators No concurrent hormone replacement therapy Concurrent thyroid hormone supplementation allow Radiotherapy See Disease Characteristics Surgery Not specify Other More 30 day since prior investigational medication More 3 month since prior oral vitamin A supplement great recommend daily requirement ( 5,000 IU ) therapeutic oral topical vitamin A derivative ( e.g. , isotretinoin ) No concurrent participation study investigational agent No concurrent medication know associated pancreatic toxicity increase triglyceride level</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>breast cancer</keyword>
</DOC>